DGI-032 Epidemiological Monitoring of Pemetrexed Use in Malignant Pleural Mesothelioma: A Tool of Local Decision Making
نویسندگان
چکیده
منابع مشابه
Pemetrexed in malignant pleural mesothelioma.
Malignant pleural mesothelioma (MPM) is a disease with a poor prognosis, related in part to the aggressiveness of this disease, and in part due to the lack of drugs that have demonstrated tumor activity. Historically, antifolates such as methotrexate have been the most active drugs in the treatment of mesothelioma. Newer antifolates have recently demonstrated higher efficacy than older regimens...
متن کاملPemetrexed in malignant pleural mesothelioma.
PURPOSE This report describes the data and analysis leading to the approval of pemetrexed (LY 231514, MTA, Alimta, Eli Lilly and Co., Indianapolis, IN) by the U.S. Food and Drug Administration (FDA) of a New Drug Application for the treatment of malignant pleural mesothelioma (MPM). EXPERIMENTAL DESIGN The FDA review of the efficacy and safety of pemetrexed assessed in a randomized clinical t...
متن کاملPemetrexed in the treatment of malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is a relatively uncommon tumor that is increasing in frequency in most areas of the world. For example, in the UK there has been a sharp increase in the number of cases since the late 1970s, a trend which is predicted to reach its peak by approximately 2015, when over 2000 cases per annum are likely to be diagnosed [1]. It is a tumor which is, in the vast ma...
متن کاملMalignant pleural mesothelioma: an epidemiological perspective.
This paper reviews the aetiology, distribution and projected future incidence of malignant mesothelioma. Asbestos exposure is the most thoroughly established risk factor. Debate continues regarding the relative importance of the different asbestos fibre types and the contribution of Simian virus 40 (SV40). Disease incidence varies markedly within and between countries. The highest annual rates ...
متن کاملA retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma.
BACKGROUND The current standard first-line chemotherapy for malignant pleural mesothelioma (MPM) is pemetrexed and cisplatin. However, other regimens, with or without a platinum agent, are reported to be effective in the treatment of MPM. PATIENTS AND METHODS Patients who were diagnosed with MPM and treated with chemotherapy between January 1999 and June 2010 at the Osaka Prefectural Medical ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Hospital Pharmacy
سال: 2013
ISSN: 2047-9956,2047-9964
DOI: 10.1136/ejhpharm-2013-000276.298